Browsing Tag
James Porter
2 posts
Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data
Nuvalent’s AACR 2026 zidesamtinib data could reshape the ROS1 NSCLC treatment debate ahead of its FDA decision. Read what it means now.
Nuvalent’s stock jumps 22% after ESMO 2024 – what’s next for this biotech game-changer?
Nuvalent, Inc., a biopharmaceutical company specialising in targeted cancer therapies, has seen its stock price skyrocket following the…